Publications (20)34.1 Total impact
-
Article: In vivo identification of sentinel lymph nodes using MRI and size-controlled and monodispersed magnetite nanoparticles.
[show abstract] [hide abstract]
ABSTRACT: PURPOSE: To develop a sentinel lymph node (SN) identification method using accurately synthesized magnetic nanoparticles (MNPs), as an enhanced specific SN tracer in combination with magnetic resonance imaging (MRI) in intact rodent and SN metastasis models. MATERIALS AND METHODS: Three sizes of MNPs were originally synthesized. We developed an experimental rat SN model, with brachial lymph nodes (Br) as the SN and the axillary lymph node (Ax) as the second lymph node, and injection of MNPs via the front paw. SN detectability was evaluated in vivo using T1 -weighted MR images after injection of the synthesized MNPs, and the amount of iron in the Br and in the Ax was assessed using inductively coupled plasma optical emission spectrometry. RESULTS: The highest ratios of the amount of iron in the Br versus the Ax were 3.1 and 3.3, using 20-nm MNPs after 2- and 24-hour injections. The appropriate dose and particle diameter for MRI detection was optimized, and the SN was optimally distinguished in the normal and metastatic rat models using MRI after a 0.4 mg/kg 20-nm MNP injection. CONCLUSION: We developed and optimized a useful SN identification method using MRI in rodent models. J. Magn. Reson. Imaging 2013;. © 2013 Wiley Periodicals, Inc.Journal of Magnetic Resonance Imaging 04/2013; · 2.70 Impact Factor -
Article: Large liposarcoma developing in the ischiorectal fossa: Report of a rare case.
[show abstract] [hide abstract]
ABSTRACT: INTRODUCTION: We herein report an extremely rare case of a liposarcoma developing in the ischiorectal fossa that was completely resected using a transsacral approach. PRESENTATION OF CASE: A 74-year-old man was admitted to our institute because of a large perianal tumor. A pelvic magnetic resonance imaging (MRI) revealed an 8cm×7cm×5cm sized encapsulated heterogeneous tumor on the right side of the ischiorectal fossa. Transsacral excision was performed under a diagnosis of liposarcoma. The tumor was partially fixed to the external sphincter and puborectalis. Therefore, the muscles were partially resected to ensure sufficient margins. Histopathological examination revealed a well differentiated liposarcoma and negative surgical margins. DISCUSSION: The basic treatment strategy of liposarcoma is surgical resection, whereas the effects of chemotherapy or radiotherapy remain limited. Although no postoperative adjuvant therapy has been performed in our case, no recurrences have occurred for 1 year after surgery. CONCLUSION: Although the curative resection of large tumors located in the ischiorectal fossa is usually difficult, the complete resection of liposarcoma is the main potentially curative treatment. A transsacral approach is useful for a complete resection.International journal of surgery case reports. 10/2012; 4(1):51-53. -
Article: Suppression of heat shock protein 27 expression promotes 5-fluorouracil sensitivity in colon cancer cells in a xenograft model.
[show abstract] [hide abstract]
ABSTRACT: The present study investigates whether the expression levels of heat shock protein 27 (HSP27) in colon cancer cells are associated with 5-fluorouracil (5-FU) sensitivity in a xenograft model, as well as the mechanism responsible for regulating 5-FU sensitivity. HCT116 cells which have a high expression of HSP27 were stably transfected with specific short hairpin RNA (shRNA) in order to suppress HSP27 expression. The association between HSP27 protein expression levels and 5-FU sensitivity was evaluated in a mouse xenograft model. The mRNA expression of 5-FU metabolic enzymes and cell apoptosis were also analyzed in the transfected cells. The suppression of HSP27 protein expression led to enhanced 5-FU sensitivity. The mRNA expression levels of dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase, but not those of thymidylate synthase, and the number of apoptotic cells increased in the transfected cells after 5-FU exposure. In conclusion, the suppression of HSP27 expression in colon cancer cells may promote 5-FU sensitivity by inducing apoptosis, despite the acceleration in 5-FU metabolism.Oncology Reports 07/2012; 28(4):1269-74. · 1.84 Impact Factor -
Article: [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
[show abstract] [hide abstract]
ABSTRACT: As pharmacokinetics in patients undergoing haemodialysis is different from patients with normal renal function, it remains unclear whether chemotherapy can be performed safely for patients with haemodialysis as well as those who have normal renal function. Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control. A 47-year-old woman had undergone haemodialysis for 10 years due to chronic renal failure. At 45 years of age, she received abdominoperineal resection due to rectal cancer (pStage II). Four months after the surgery, liver metastasis was found, for which partial resection of the liver and adjuvant chemotherapy [UFT (400 mg/body)/UZEL (75 mg/body)] were performed. Eighteen months after the liver resection, multiple lung metastases were found. Therefore, intensive chemotherapy using FOLFIRI (CPT-11: 90 mg/m2) with bevacizumab (2.5 mg/m2) was performed. Severe neutropenia (grade 3, 4), but not non-hematologic adverse events such as diarrhea and bevacizumab-specific adverse events, was observed. As she did not recover easily from neutropenia in spite of treatment with G-CSF, a dose reduction of the FOLFIRI regimen was gradually performed. Although chemotherapy was conducted approximately monthly, the tumor response reflected a stable disease 8 months after 8 courses of chemotherapy. We suggest that it is important to investigate the pharmacokinetics of toxic agents such as CPT-11, (SN38) for dose modification, and for the safe and continuous chemotherapy of patients receiving haemodialysis.Gan to kagaku ryoho. Cancer & chemotherapy 06/2012; 39(6):983-6. -
Article: Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
[show abstract] [hide abstract]
ABSTRACT: We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007. S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9). S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%). The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.Surgery Today 11/2011; 42(2):164-8. · 1.22 Impact Factor -
Article: Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.
[show abstract] [hide abstract]
ABSTRACT: Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials. Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.International Journal of Clinical Oncology 09/2011; 17(4):412-6. · 1.41 Impact Factor -
Article: [Current status of robotic surgery for colorectal cancer and its future perspectives].
Nippon rinsho. Japanese journal of clinical medicine 04/2011; 69 Suppl 3:414-7. -
Article: [Current view and possibilities of chemotherapy sensitivity and resistance assays and metabolic enzyme analysis in individualized chemotherapy for the patients with colorectal cancer].
Nippon rinsho. Japanese journal of clinical medicine 04/2011; 69 Suppl 3:487-93. -
Article: A case of IgA-related enteropathy complicated with gastrointestinal bleeding and progressive IgA nephropathy: a possible variant Henoch-Schönlein purpura?
[show abstract] [hide abstract]
ABSTRACT: Here, we report an adult patient with IgA-related enteropathy complicated with massive intestinal bleeding and acute renal failure, but without skin lesions. Surgical resection of the small intestine and steroid pulse therapy was performed. Histopathology revealed significant deposition of IgA and C3 in the small vessels of the intestine and the kidney mesangium. Although skin purpura was absent, the histopathology and clinical manifestations suggested that the pathophysiology was similar to Henoch-Schönlein purpura (HSP), implying IgA-related enteropathy as a subclass of HSP. Retrospective analysis indicates that terminal ileum lesions may be a poor prognostic indicator.Internal Medicine 01/2010; 49(16):1755-61. · 0.94 Impact Factor -
Article: Prolapse of Intussusception through the Anus as a Result of Sigmoid Colon Cancer.
[show abstract] [hide abstract]
ABSTRACT: Adult intussusception is rare and most often associated with cancer. We report a case of intussuscepted sigmoid colon into the rectum protruding from the anus of a 47-year-old woman. The cause of the intussusception was sigmoid colon cancer. We removed the intussuscepted part of the sigmoid colon as well as the rectum and regional lymph nodes. The patient recovered uneventfully and there has been no evidence of recurrence of the cancer.Case Reports in Gastroenterology 01/2010; 4(3):346-350. -
Article: Impact of visceral obesity on short-term outcome after laparoscopic surgery for colorectal cancer: a single Japanese center study.
[show abstract] [hide abstract]
ABSTRACT: This prospective study was conducted to clarify the association between the short-term outcome of laparoscopic colorectal surgery and visceral obesity (VO) based on waist circumference (WC). WC and body mass index (BMI) were preoperatively measured in 98 consecutive patients with colorectal cancer undergoing laparoscopic surgery between June 2004 and February 2006. VO was defined as both BMI >or=25 kg/m2 and WC >or=85 cm in male patients, or WC >or=90 cm in female patients. The patients were divided into VO (n=21) and non-VO (n=77). Systemic complications were significantly more frequent in VO than in non-VO (19.0% vs. 3.9%, P=0.036), and VO was the only significant independent risk factor (odds ratio 8.1, P=0.018). BMI itself had no impact on outcome. WC is a potentially useful index for the assessment of surgical risk in laparoscopic colorectal surgery.Surgical laparoscopy, endoscopy & percutaneous techniques 08/2009; 19(4):324-7. · 1.23 Impact Factor -
Article: Hand-assisted versus conventional laparoscopic restorative proctocolectomy for ulcerative colitis.
[show abstract] [hide abstract]
ABSTRACT: In a few comparative and randomized studies, hand-assisted laparoscopic restorative proctocolectomy (HALS-RP) maintained the advantages of a minimally invasive approach with some potential benefits. However, the role of HALS-RP has not been defined. The aim of this study was to evaluate the effectiveness of HALS-RP compared with a conventional laparoscopic restorative proctocolectomy (LAP-RP) in patients with ulcerative colitis. A retrospective study was conducted using a prospectively maintained database to compare a consecutive series of 30 patients who underwent HALS-RP from June 2004 to September 2007 with 40 patients who underwent LAP-RP from October 1994 to June 2004 in our institution. Patient characteristics, perioperative parameters, and the surgical outcomes were assessed. Mann-Whitney U and Fisher exact tests were used for statistical analysis. Both groups were well matched with no differences in sex, body mass index, periods from diagnosis, American Society of Anesthesiologists score, performance status, preoperative blood chemistry or steroid, and cyclosporine usage. The median operative time was significantly shorter for HALS-RP [356 (range: 176 to 590) min] than for LAP-RP [505 (range: 360 to 785) min; P<0.001]. The median length of incision was significantly longer for HALS-RP [8 (range: 7.5 to 8) cm] than for LAP-RP [5.5 (range: 5 to 8) cm]. The estimated blood loss and the length of hospital stay were similar between the 2 groups. The incidence of postoperative complications including anastomotic leakage did not differ between the 2 groups (P=0.437). HALS-RP significantly reduced the operative time compared with the conventional LAP-RP, while retaining the acceptable morbidity rates and recovery benefits associated with minimally invasive surgery. HALS-RP is likely to replace a conventional laparoscopic approach for this technically challenging procedure.Surgical laparoscopy, endoscopy & percutaneous techniques 03/2009; 19(1):52-6. · 1.23 Impact Factor -
Article: Adenosquamous carcinoma of the sigmoid colon treated by the less invasive procedures of endoscopy and laparoscopy: report of a case.
[show abstract] [hide abstract]
ABSTRACT: A 51-year-old man demonstrated a positive finding for a fecal occult blood test during a screening examination. Total colonoscopy was therefore performed, and a semi-pedunculated polyp was detected in the sigmoid colon. Although this polyp was suspected of invading the submucosal layer, it was removed endoscopically because the preoperative diagnosis was well-differentiated adenocarcinoma. The pathological findings revealed adenosquamous carcinoma that had invaded the submucosal layer with lymphatic invasion. A laparoscopic bowel resection was then performed and a histopathological examination of the surgical specimen showed metastasis to two regional lymph nodes. The patient is alive and recurrence-free 22 months after the operation. Adenosquamous carcinoma has been reported to be rare and to possess a highly metastatic potential. It consists of both squamous cells and glandular cell components. We report a case of adenosquamous carcinoma of the sigmoid colon treated by less invasive approaches consisting of an endoscopic mucosal resection and a subsequent laparoscopic colectomy.Surgery Today 01/2009; 39(11):994-7. · 1.22 Impact Factor -
Article: Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer.
[show abstract] [hide abstract]
ABSTRACT: The resistance of colon cancer to 5-fluorouracil (5-FU) is a critical issue, and the cause of this resistance cannot always be explained based on the known molecules. Heat shock protein 27 (HSP27) mRNA expression has recently been shown to be correlated with 5-FU resistance in 5-FU-resistant cell lines. In this study, we attempted to elucidate the functional mechanism of HSP27 in 5-FU resistance in colon cancer. HSP27 protein levels in several human colon cancer cell lines (LoVo, HCT15, WiDr, HCT116, HT-29 and SW480) were determined by immunoblot and densitometry analysis. The in vitro growth inhibition rates (IR) of the cell lines at various concentrations of 5-FU were assessed by MTT assay. The degree of 5-FU resistance was estimated as the drug concentration inducing 50% IR (IC50). The HSP27 protein level and IC50 were significantly correlated in these cell lines (p=0.010). The effect of HSP27 overexpression on IC50 was evaluated in LoVo cells. HSP27 transfectants significantly increased IC50 and reduced HSP27 resistance. The effect of HSP27 down-regulation by HSP27 siRNA on IC50 was confirmed in HCT15 cells. HSP27 siRNA suppressed HSP27 protein levels and reduced IC50 in a dose-dependent manner. These data indicated that HSP27 is closely connected with 5-FU resistance in colon cancer and suggested that HSP27 levels predicted 5-FU resistance. HSP27 down-regulation overcame 5-FU resistance and HSP27 may be a clinical target in patients with 5-FU-resistant colon cancer.Oncology Reports 12/2008; 20(5):1165-72. · 1.84 Impact Factor -
Article: Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
[show abstract] [hide abstract]
ABSTRACT: We aimed to evaluate the safety and efficacy of combination chemotherapy with biweekly irinotecan (CPT-11) plus oral tegafur/uracil (UFT) and leucovorin (LV) in patients with previously untreated metastatic colorectal adenocarcinoma in phase I/II setting. We recruited 37 patients with histologically proven metastatic colorectal adenocarcinoma. UFT (300 mg/m(2) per day) and LV (75 mg/day) were administered orally on days 1-21. CPT-11 was administered intravenously on day 1 and 15, at an initial dose of 60 mg/m(2), stepping up to 150 mg/m(2) in a traditional phase I fashion. The treatment was repeated every 4 weeks. After patients enrolled into a phase II portion, the efficacy and toxicity of this regimen were also assessed. The recommended dose of CPT-11 was determined to be 150 mg/m(2). Although one patient had a pulmonary embolism after 60 mg/m(2) of CPT-11, the treatment was well tolerated in general. The overall objective response rate was 37.8% (14/37; 95% CI, 22.5-55.2) in all patients. Median progression-free survival was 226 days (95% CI, 133-276). Biweekly CPT-11 plus UFT and LV had a reasonable safety profile with manageable toxicity, and had a promising activity in patients with metastatic colorectal cancer. Further trials are indicated based on the promising results observed in this study.Cancer Chemotherapy and Pharmacology 06/2008; 63(3):501-7. · 2.83 Impact Factor -
Article: Epstein-Barr virus-positive inflammatory pseudotumor of the spleen with concomitant rectal cancer: a case report and review of the literature.
Digestive Diseases and Sciences 11/2007; 52(10):2806-12. · 2.12 Impact Factor -
Article: In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer.
[show abstract] [hide abstract]
ABSTRACT: In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 tumor tissue was transplanted onto the wall of the cecum and G207 was injected in the established cecum tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intratumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intratumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intratumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves tumor-specific T-cell responses.Cancer Gene Therapy 03/2002; 9(2):142-8. · 2.80 Impact Factor -
Article: Serrated adenoma developing into advanced colon cancer in 2 years.
[show abstract] [hide abstract]
ABSTRACT: We report the case of a 76-year-old woman with a flat elevated lesion (laterally spreading tumor; LST) in the transverse colon that had been identified 2 years before the current presentation. Pathologically, the lesion had been diagnosed as a serrated adenoma with severe dysplasia. The patient had refused endoscopic resection because she was afraid of the risk of colonic perforation; she did not come to follow-up until 2 years after the diagnosis, when she had advanced colon cancer in the transverse colon where the LST had been detected. Histopathological examination confirmed a poorly differentiated adenocarcinoma with no adenomatous component such as had been found in the LST lesion.Journal of Gastroenterology 02/2002; 37(6):467-70. · 4.16 Impact Factor -
Article: Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer.
[show abstract] [hide abstract]
ABSTRACT: Transforming growth factor beta1 (TGF-beta1) is thought to be involved in cancer growth and progression. TGF-beta1 changes to its active form after being secreted in its latent form. Our aim was to clarify the significance of plasma concentrations of active and total TGF-beta1 of patients with colorectal cancer. Plasma concentrations of active and total TGF-beta1 in 45 patients with colorectal cancer and 23 healthy volunteers were measured using ELISA and the activation rate (ratio of active to total TGF-beta1) was determined. Plasma concentrations of active TGF-beta1 (21.9 +/- 12.8 pg/ml) were significantly higher in patients with colorectal cancer than in healthy volunteers (9.9 +/- 5.9 pg/ml; p < 0.001, Welch's t-test). Concentration of total TGF-beta1 was also significantly higher for patients with colorectal cancer (18.0 +/- 13.0 ng/ml vs. 11.1 +/- 6.4 ng/ml; p < 0.01, Welch's t-test). However, there was no significant difference in the TGF-beta1 activation rate between the 2 groups. There was a correlation between Dukes' stage and plasma concentration of active or total TGF-beta1 (p < 0.01, Spearman's rank correlation test) and on day 7 the active TGF-beta1 levels for patients recovering from curative resection were similar to those of the control group of healthy volunteers. These results suggest that active TGF-beta1 might be used as a tumor marker for colorectal cancer.International Journal of Cancer 02/2002; 97(4):508-11. · 5.44 Impact Factor -
Article: Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer.
[show abstract] [hide abstract]
ABSTRACT: Epidemiologic studies indicate that the use of nonsteroidal anti-inflammatory drugs, which inhibit cyclooxygenase activity, reduce the risk of colorectal cancer. In addition, several studies demonstrate increased expression of cyclooxygenase-2 in human colorectal cancer tissues. However, the role of cyclooxygenase-2 expression in colorectal cancer has not yet been fully established. The aim of this study was to clarify the clinicopathologic significance of cyclooxygenase-2 expression in human colorectal cancer. A total of 232 surgically resected colorectal cancer specimens were analyzed immunohistochemically with the use of a murine anti-human cyclooxygenase-2 monoclonal antibody. Cyclooxygenase-2 expression was then compared with clinicopathologic background and survival outcome. Cyclooxygenase-2 was expressed in the cytoplasm of the cancer cells but not in normal epithelium. Cyclooxygenase-2 expression was noted in 71.6 percent (166/232) of the cancer patients and correlated significantly with histologic type (P = 0.033), depth of invasion (P = 0.016), pathologic stage (P = 0.020), and metachronous liver metastasis (P = 0.001). Multivariate analysis for factors associated with metachronous liver metastasis showed that cyclooxygenase-2 expression was one of the independent risk factors, second only to lymph node metastasis. Patients with cyclooxygenase-2 expression showed a significantly poorer outcome compared with those without cyclooxygenase-2 expression (P = 0.002). Cyclooxygenase-2 expression in the primary lesion may be a useful marker for evaluating prognosis and liver metastasis in patients with colorectal cancer.Diseases of the Colon & Rectum 02/2002; 45(1):98-103. · 3.13 Impact Factor
Top co-authors
Top Journals
Institutions
-
2002–2013
-
Keio University
- Department of Surgery
Tokyo, Tokyo-to, Japan
-
